Updated CRYSTAL Data Support Effectiveness of Cetuximab (Erbitux) in Wild-Type KRAS Metastatic Colorectal Cancer
At the 2010 Gastrointestinal Cancers Symposium, new data from the
CRYSTAL trial identified BRAF gene mutations as a poor prognostic indicator in metastatic colorectal cancer (mCRC) but not predictive of response to therapy.
Reviewing Initial Therapy and Maintenance in NSCLC
NCCN included a dinner symposium on Maintenance Therapy for Non-Small Cell Lung Cancer.
2 Clarke Drive Cranbury, NJ 08512